[Bowenoid actinic keratosis: therapy with intralesional injection of recombinant beta-interferon].
Biopsy-proven bowenoid actinic keratosis located in the pretibial region in each of two elderly women (61 and 81 years) were treated with intralesional injections with a new recombinant beta-interferon. The treatment took the form of intralesional injections three times a week over 3 consecutive weeks. The dose per single injection was 1.5 or 1.0 MU interferon, respectively. Clinical and histological examinations showed a complete response in both patients. Controls up to 18 months showed no relapse. There were no flu-like side-effects. Leukocyte counts decreased by 2700 and 500 cells per microliter during therapy.
Kowalzick
L
L
Universitäts-Hautklinik Hamburg-Eppendorf.
Mensing
H
H
Weyer
U
U
Kimmig
W
W
Brzoska
J
J
D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D001913:Bowen's Disease / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D016899:Interferon-beta / Q000008:administration & dosage*; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D012867:Skin / Q000473:pathology; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy*
D011994:Recombinant Proteins; D016899:Interferon-beta
Bowenoide aktinische Keratose: Therapie durch intraläsionale Injektion von rekombinantem beta-Interferon.